Detalhe da pesquisa
1.
Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2.
Bioorg Med Chem Lett
; 29(4): 674-680, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522953
2.
Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery.
Expert Opin Drug Metab Toxicol
; 2(2): 325-37, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16866617
3.
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
J Med Chem
; 58(3): 1159-83, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25590515
4.
The emerging importance of predictive ADME simulation in drug discovery.
Drug Discov Today
; 7(2): 109-16, 2002 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11790621
5.
In silico prediction of ADME properties: are we making progress?
Curr Opin Drug Discov Devel
; 7(1): 36-42, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14982146
6.
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
J Med Chem
; 57(3): 921-36, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24354345
7.
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.
ACS Med Chem Lett
; 4(1): 85-90, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900567
8.
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
J Med Chem
; 55(22): 9416-33, 2012 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22985112
9.
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.
Bioorg Med Chem Lett
; 14(7): 1709-12, 2004 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-15026055